TPST logoTPST
Tempest Therapeutics Inc

13,186
Loading...
Loading...
News
all
press releases
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Zacks·3mo ago
News Placeholder
More News
News Placeholder
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger
CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.
Stocktwits·5mo ago
News Placeholder
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin...
Benzinga·1y ago
News Placeholder
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients...
Benzinga·1y ago
News Placeholder
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
Glancy Prongay & Murray LLP (GPM) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors and officers possible violations of state laws. If...
Business Wire·1y ago
News Placeholder
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
TPST-1120, a first-in-class, oral, selective PPAR antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data...
Globe Newswire·1y ago
News Placeholder
Tempest Therapeutics, Inc. (NASDAQ:TPST) Expected to Post Q1 2024 Earnings of ($0.36) Per Share
Tempest Therapeutics, Inc. (NASDAQ:TPST Free Report) HC Wainwright issued their Q1 2024 earnings estimates for Tempest Therapeutics in a report released on Wednesday, March 20th...
Zolmax·1y ago
News Placeholder
Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright
Tempest Therapeutics (NASDAQ:TPST Get Free Report)s stock had its buy rating restated by HC Wainwright in a research report issued to clients and investors on Wednesday...
Zolmax·1y ago
News Placeholder
Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by William Blair
Tempest Therapeutics (NASDAQ:TPST Get Free Report)s stock had its outperform rating restated by investment analysts at William Blair in a note issued to investors on...
Zolmax·1y ago
News Placeholder
Tempest Reports Year End 2023 Financial Results and Provides Business Update
Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in two...
Globe Newswire·1y ago

Latest TPST News

View

Advertisement. Remove ads.

Advertisement. Remove ads.